Deferred Tax Assets, Valuation Allowance of AbbVie Inc. from 31 Dec 2012 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
AbbVie Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2012 to 31 Dec 2025.
  • AbbVie Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $15,018,000,000, a 1.3% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

AbbVie Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $15,018,000,000 +$195,000,000 +1.3% 31 Dec 2025 10-K 20 Feb 2026 2025 FY
Q4 2024 $14,823,000,000 +$1,345,000,000 +10% 31 Dec 2024 10-K 20 Feb 2026 2025 FY
Q4 2023 $13,478,000,000 +$3,851,000,000 +40% 31 Dec 2023 10-K 14 Feb 2025 2024 FY
Q4 2022 $9,627,000,000 +$236,000,000 +2.5% 31 Dec 2022 10-K 20 Feb 2024 2023 FY
Q4 2021 $9,391,000,000 +$8,188,000,000 +681% 31 Dec 2021 10-K 17 Feb 2023 2022 FY
Q4 2020 $1,203,000,000 +$472,000,000 +65% 31 Dec 2020 10-K 18 Feb 2022 2021 FY
Q4 2019 $731,000,000 +$628,000,000 +610% 31 Dec 2019 10-K 19 Feb 2021 2020 FY
Q4 2018 $103,000,000 -$5,000,000 -4.6% 31 Dec 2018 10-K 21 Feb 2020 2019 FY
Q4 2017 $108,000,000 +$32,000,000 +42% 31 Dec 2017 10-K 27 Feb 2019 2018 FY
Q4 2016 $76,000,000 +$6,000,000 +8.6% 31 Dec 2016 10-K 16 Feb 2018 2017 FY
Q4 2015 $70,000,000 -$102,000,000 -59% 31 Dec 2015 10-K 17 Feb 2017 2016 FY
Q4 2014 $172,000,000 +$129,000,000 +300% 31 Dec 2014 10-K 19 Feb 2016 2015 FY
Q4 2013 $43,000,000 +$36,000,000 +514% 31 Dec 2013 10-K 20 Feb 2015 2014 FY
Q4 2012 $7,000,000 31 Dec 2012 10-K 21 Feb 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.